Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

77.96USD
20 Feb 2018
Change (% chg)

$-3.62 (-4.44%)
Prev Close
$81.58
Open
$80.86
Day's High
$81.90
Day's Low
$77.22
Volume
88,674
Avg. Vol
86,840
52-wk High
$95.64
52-wk Low
$27.53

Latest Key Developments (Source: Significant Developments)

Enanta Pharmaceuticals Reports Q1 Earnings Per Share $0.59
Wednesday, 7 Feb 2018 04:01pm EST 

Feb 7 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017.Q1 EARNINGS PER SHARE $0.59.Q1 REVENUE $38.1 MILLION VERSUS $10.4 MILLION.  Full Article

Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated
Friday, 5 Jan 2018 07:30am EST 

Jan 5 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED.ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY "INTREPID" OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED.ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS.  Full Article

Enanta Pharma Q4 earnings per share $1.86
Monday, 20 Nov 2017 04:01pm EST 

Nov 20 (Reuters) - Enanta Pharmaceuticals Inc ::Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017.Q4 earnings per share $1.86.Q4 revenue $75.9 million versus I/B/E/S view $73.1 million.Q4 earnings per share view $2.13 -- Thomson Reuters I/B/E/S.  Full Article

Enanta Pharmaceuticals announces new data presentations on EDP-305
Wednesday, 27 Sep 2017 04:14pm EDT 

Sept 27 (Reuters) - Enanta Pharmaceuticals Inc :Enanta Pharmaceuticals announces new data presentations on EDP-305, an FXR agonist for NASH and PBC, at The Liver Meeting 2017.Co has submitted an abstract to AASLD for consideration of late breaking data from its phase 1 clinical study of EDP-305​.  Full Article

Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c
Wednesday, 27 Sep 2017 06:30am EDT 

Sept 27 (Reuters) - Enanta Pharmaceuticals Inc :Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c.Enanta Pharmaceuticals - co expects to receive $15 million milestone payment from Abbvie in quarter ending Dec 31, 2017, upon price reimbursement approval of Maviret in Japan​.Enanta Pharma - expects to get $15 million milestone payment from Abbvie in quarter ending Dec 31, 2017, upon Japan​ price reimbursement approval of Maviret.Enanta Pharmaceuticals -‍in Japan, Maviret is also approved as 12-week option for patients infected with GT3-6, patients with specific challenges​.  Full Article

Enanta pharmaceuticals Q3 loss per share $0.44
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Enanta Pharmaceuticals Inc :Enanta pharmaceuticals reports financial results for its fiscal third quarter ended june 30, 2017.Q3 loss per share $0.44.Q3 revenue $7.5 million versus i/b/e/s view $8.1 million.Q3 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

EC grants Abbvie's Maviret marketing authorization for treatment of Chronic Hepatitis C
Friday, 28 Jul 2017 10:57am EDT 

July 28 (Reuters) - Abbvie Inc ::European Commission grants Abbvie's Maviret (glecaprevir/pibrentasvir) marketing authorization for the treatment of Chronic Hepatitis C in all major genotypes (GT1-6).‍Approval of Maviret is supported by data from eight registrational studies in Abbvie's clinical development program​.  Full Article

Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET
Friday, 23 Jun 2017 07:44am EDT 

June 23 (Reuters) - Enanta Pharmaceuticals Inc :Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6).Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6).Says ‍final european commission decision expected q3 2017​.  Full Article

Enanta Pharmaceuticals reports Q2 loss per share $0.28
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - Enanta Pharmaceuticals Inc :Enanta Pharmaceuticals reports financial results for its fiscal second quarter ended March 31, 2017.Q2 loss per share $0.28.Q2 revenue $9.0 million versus I/B/E/S view $9.2 million.Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir
Tuesday, 14 Mar 2017 08:00am EDT 

Abbvie Inc : Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c .Priority review follows EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively.  Full Article

BRIEF-Enanta Pharmaceuticals Reports Q1 Earnings Per Share $0.59

* ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017